Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE ceftaroline surveillance program

Clinical Infectious Diseases

Volumn 55, Issue SUPPL. 3, 2012, Pages

  Sader, Helio S ^a   Flamm, Robert K ^a   Farrell, David J ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; TETRACYCLINE; VANCOMYCIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; CHILD; CONTROLLED STUDY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CHILD; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; STAPHYLOCOCCUS AUREUS; YOUNG ADULT;

EID: 84865218844     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis560     Document Type: Article

References (27)

1. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staph-ylococcus aureus. Clin Infect Dis 2008; 46(Suppl 5):S344-9.
2. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 2009; 15:1516-8.
3. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006; 368:874-85.
4. Deleo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated methicillin-resistant Staphylococcus aureus. Lancet 2010; 375:1557-68.
5. Klevens RM, Edwards JR, Richards CL Jr., et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007; 122:160-6.
6. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother 2009; 64:441-6.
7. Garau J, Bouza E, Chastre J, Gudiol F, Harbarth S. Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol Infect 2009; 15:125-36.
8. Biek D, Critchley IA, Riccobene TA, Thye DA. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Grampositive activity. J Antimicrob Chemother 2010; 65:iv9-16.
9. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalospo-rin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011; 52:1156-63.
10. Forest Laboratories, Inc. Teflaro. Package insert. Revised May 2012. Available at http://www.frx.com/pi/Teflaro-pi.pdf. Accessed 27 June 2012.
11. Clinical and Laboratory Standards Institute. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobi-cally; approved standard. 8th ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
12. Clinical and Laboratory Standards Institute. M100-S22. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
13. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7:629-41.
14. Talan DA, Krishnadasan A, Gorwitz RJ, et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011; 53:144-9.
15. Charlebois ED, Perdreau-Remington F, Kreiswirth B, et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004; 39:47-54.
16. Popovich KJ, Weinstein RA, Hota B. Are community-associated meth-icillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis. 2008; 46:787-94.
17. Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008; 148:249-57.
18. Leclercq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clin Microbiol Infect 2009; 15:224-31.
19. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med 2002; 162: 682-8.
20. David MZ, Crawford SE, Boyle-Vavra S, Hostetler MA, Kim DC, Daum RS. Contrasting pediatric and adult methicillin-resistant Staph-ylococcus aureus isolates. Emerg Infect Dis 2006; 12:631-7.
21. Jones RN, Biedenbach DJ, Beach ML. Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): Report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003; 46: 77-80.
22. Coco AS, Horst MA, Gambler AS. Trends in broad-spectrum antibiotic prescribing for children with acute otitis media in the United States, 1998-2004. BMC Pediatr 2009; 9:41.
23. Llor C, Cots JM, Gaspar MJ, Alay M, Rams N. Antibiotic prescribing over the last 16 years: fewer antibiotics but the spectrum is broadening. Eur J Clin Microbiol Infect Dis 2009; 28:893-7.
24. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65(Suppl 4): iv67-71.
25. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 2011; 66:iii53-59.
26. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vanco-mycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641-50.
27. File TM Jr., Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395-405.